- Home
- OUST vs NUVB Comparison
OUST vs NUVB Comparison
Compare OUST & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUST
- NUVB
- Stock Information
- Founded
- OUST 2015
- NUVB 2018
- Country
- OUST United States
- NUVB United States
- Employees
- OUST N/A
- NUVB N/A
- Industry
- OUST Industrial Machinery/Components
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- OUST Technology
- NUVB Health Care
- Exchange
- OUST Nasdaq
- NUVB Nasdaq
- Market Cap
- OUST 1.1B
- NUVB 1.1B
- IPO Year
- OUST N/A
- NUVB N/A
- Fundamental
- Price
- OUST $29.86
- NUVB $3.70
- Analyst Decision
- OUST Strong Buy
- NUVB Strong Buy
- Analyst Count
- OUST 6
- NUVB 7
- Target Price
- OUST $23.83
- NUVB $8.43
- AVG Volume (30 Days)
- OUST 3.0M
- NUVB 7.2M
- Earning Date
- OUST 11-06-2025
- NUVB 11-05-2025
- Dividend Yield
- OUST N/A
- NUVB N/A
- EPS Growth
- OUST N/A
- NUVB N/A
- EPS
- OUST N/A
- NUVB N/A
- Revenue
- OUST $125,848,000.00
- NUVB $14,355,000.00
- Revenue This Year
- OUST $33.30
- NUVB $332.80
- Revenue Next Year
- OUST $36.50
- NUVB $360.12
- P/E Ratio
- OUST N/A
- NUVB N/A
- Revenue Growth
- OUST 26.37
- NUVB 900.35
- 52 Week Low
- OUST $6.06
- NUVB $1.54
- 52 Week High
- OUST $36.25
- NUVB $4.09
- Technical
- Relative Strength Index (RSI)
- OUST 51.77
- NUVB 65.98
- Support Level
- OUST $26.29
- NUVB $2.99
- Resistance Level
- OUST $28.95
- NUVB $3.95
- Average True Range (ATR)
- OUST 2.42
- NUVB 0.24
- MACD
- OUST -0.38
- NUVB 0.03
- Stochastic Oscillator
- OUST 37.54
- NUVB 73.96
About OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.